CVR CRUSH
- Funded by UK Research and Innovation (UKRI)
- Total publications:0 publications
Grant number: C19-IUC-270
Grant search
Key facts
Disease
COVID-19Funder
UK Research and Innovation (UKRI)Principal Investigator
PendingResearch Location
United KingdomLead Research Institution
MRC-University of Glasgow Centre for Virus ResearchResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The CVR has established "CRUSH" (COVID-19 Drug-Screening and Resistance Hub) for the benefit of the UK academic and industrial community. CRUSH is a facility fully dedicated to screen anti-SARS-CoV2 drugs/ monoclonal antibodies and characterise the potential drug-resistant mutations induced by possible lead compounds. CRUSH will also monitor the presence of SARS-CoV-2 globally circulating strains with potential drug-resistant mutations and curate an open access database with this information.